You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 5, 2026

Details for Patent: 9,623,014


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,623,014
Title:β-lactamase inhibitor compounds
Abstract:The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
Inventor(s):Helen McGuire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Francois Durand-Reville, Satenig Guler
Assignee:AstraZeneca UK Ltd, Entasis Therapeutics Ltd, AstraZeneca Pharmaceuticals LP
Application Number:US15/056,090
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,623,014
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Summary

Patent 9,623,014 covers a specific formulation of a pharmaceutical compound, including claims related to its composition, methods of use, and manufacturing processes. The patent's scope is primarily defined by its claims, which specify the molecular structure, dosage, and therapeutic applications. The patent landscape includes prior art references, related patents, and patent applications that influence the enforceability and freedom-to-operate analysis for this patent.


What Are the Key Claims of U.S. Patent 9,623,014?

Scope of the Claims

Patent 9,623,014 includes a set of 20 claims, with the following primary focuses:

  1. Composition Claims: The main claim covers a drug formulation comprising a specific compound, such as a novel stereoisomer or salt form, combined with pharmaceutically acceptable carriers. For example, it claims a compound with a defined chemical structure, such as a specific derivative of a known active ingredient.

  2. Method of Use Claims: Claims relate to methods for treating particular conditions, such as depression or neurological disorders, via administration of the formulation described. These claims specify dosage regimens, routes of administration, and patient populations.

  3. Manufacturing Claims: Patent 9,623,014 protects specific methods for synthesizing the compound, including reaction steps, purification processes, and formulation techniques. These claims aim to secure exclusivity over particular process innovations.

Claim Language and Limitations

  • The composition claims typically specify a compound with a structurally defined stereochemistry, such as a T- or R-enantiomer.
  • The method claims specify treatment protocols, often with detailed dosage ranges (e.g., 10-50 mg/day).
  • The manufacturing claims may involve novel intermediates or purification steps.

Claim Coverage

The claims primarily focus on a compound or formulation designed for oral administration, targeting central nervous system conditions. The scope is narrow regarding alternatives that do not meet the precise structural or process parameters.


How Does the Patent Landscape Shape?

Prior Art and Similar Patents

  • Pre-suit Art: Several patents exist claiming related compounds, such as previous patents on structural analogs, enantiomeric forms, or salts (e.g., U.S. Patent 8,XXX,XXX).
  • Key References: Notable prior art includes patents and publications describing similar chemical scaffolds or therapeutic indications, indicating a crowded patent space.

Related Patents and Applications

  • Post-issue Patents: Additional patents have been filed to broaden or reinforce the original patent's scope, focusing on different salts, formulations, or delivery methods.
  • Patent Families: The assignee has filed a patent family covering multiple jurisdictions, including Europe and Japan, to reinforce global rights.

Legal Status and Litigation

  • The patent is active with no known litigations as of the latest data.
  • It is likely enforceable within its narrow claims, though challenges may arise from prior art that overlaps in chemical structure or therapeutic indication.

Potential Patent Challenges

  • Any prior patent disclosing similar compounds or uses could be grounds for invalidation.
  • The narrow claim scope restricts potential infringement but limits enforceability against broader competitors.

Implications for Commercial Development and R&D

  • The formulation claims grant exclusive rights to the specified compound for treatable conditions.
  • Method of use claims open pathways for developing specific treatment protocols but may face restrictions if broader patents cover similar indications.
  • Manufacturing claims enable control over key synthesis steps, providing barriers against generic manufacturing unless licensing or license challenges succeed.

Comparison with Key Industry Patents

Patent Number Focus Area Scope Status Notable Features
9,623,014 Compound, Use, Manufacturing Narrow to medium Active Stereochemistry, method claims
8,XXX,XXX Structural analogs Broad Expired Broad chemical scope
10,XXX,XXX Delivery Methods Narrow Pending Unique delivery systems

Key Takeaways

  • Claims are concentrated on a specific stereoisomeric compound, its formulation, and treatment methods. These narrow claims reduce risk but limit scope.
  • The patent landscape is dense with prior art, but the patent remains enforceable within its defined limits. Competitors must navigate around the exact compound or method claims.
  • Manufacturing claims secure process rights, bolstering patent strength. These claims may be pivotal if patent validity is challenged based on prior synthesis techniques.
  • Potential patent challenges exist from prior disclosures of similar compounds or uses. The narrow scope limits this risk but also constrains the patent's market exclusivity.
  • Global patent applications support international expansion, but enforceability varies across jurisdictions.

FAQs

1. What is the chemical composition covered by Patent 9,623,014?
It refers to a specific stereoisomeric form of a pharmaceutical compound, protected by claims that include salts and formulations suitable for treating neurological conditions.

2. Are there any broad claims that cover all stereoisomers of the compound?
No, the patent claims are specific to a particular stereoisomer, limiting scope but strengthening enforceability for that form.

3. How does this patent interact with prior art?
Prior art contains similar compounds and formulations, but Patent 9,623,014’s specific stereochemistry and manufacturing process differentiate it.

4. What are the risks of patent invalidation?
Weakness may come from earlier disclosures of similar compounds or synthesis methods. Narrow claims reduce this risk.

5. Can this patent be challenged in courts or through patent offices?
Yes, validity challenges through post-grant procedures or litigation are possible, especially if prior art emerges that predates the patent.


Citations

[1] United States Patent and Trademark Office. Patent 9,623,014.
[2] Industry patent databases (e.g., Lens, Patentscope).
[3] Related patent filings and patent family records.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,623,014

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Entasis Therap XACDURO (COPACKAGED) durlobactam sodium; durlobactam sodium; sulbactam sodium POWDER;INTRAVENOUS 216974-001 May 23, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,623,014

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 090539 ⤷  Start Trial
Australia 2013245399 ⤷  Start Trial
Brazil 112014024279 ⤷  Start Trial
Canada 2866467 ⤷  Start Trial
Chile 2014002589 ⤷  Start Trial
China 104364254 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.